Doctor of Podiatric Medicine Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ryan Apt

Podiatrist Lake Worth, FL Doctor of Podiatric Medicine

NPI 1770071052 CMS profile 5705581

7556 Lake Worth Rd Ste 104, Lake Worth, FL 33467

Open in the dashboard

General payments

$8,124

105 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Apt of Lake Worth, FL is reported in the CMS Open Payments database as having received $8,124 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,141 14
2024 General $1,299 18
2023 General $2,081 23
2022 General $1,495 23
2021 General $1,306 24
2020 General $802 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Apt
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Ryan Apt were reported at $1,141. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Ryan Apt Podiatrist median Middle half National median
2019 $0 $196 $72–$601 $163
2020 $802 $118 $38–$335 $114
2021 $1,306 $169 $57–$573 $132
2022 $1,495 $220 $74–$782 $149
2023 $2,081 $208 $71–$635 $160
2024 $1,299 $237 $87–$681 $164
2025 $1,141 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Stryker Corporation $1,968 31 payments
  2. Integra LifeSciences Corporation $1,352 12 payments
  3. Arthrex, Inc. $802 3 payments
  4. Treace Medical Concepts, Inc. $745 9 payments
  5. Smith+Nephew, Inc. $440 11 payments
  6. Biocomposites Inc $432 4 payments
  7. Flower Orthopedics Coporation $400 9 payments
  8. Kerecis Limited $276 4 payments
  9. Linvatec Corporation $266 2 payments
  10. Organogenesis Inc. $256 5 payments
  11. Other $1,187 15 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $6,547 100 payments
  2. Education $648 1 payment
  3. Long term medical supply or device loan $507 2 payments
  4. Travel and Lodging $422 2 payments
Products named General payments · program years 2020–2025
  1. Integra Recon-Skin And Wound $1,293 11 payments
  2. VARIAX $861 15 payments
  3. PRIMATRIX $845 10 payments
  4. INTEGRA DERMAL REGENERATION TEMPLATE $845 10 payments
  5. Integra Recon-Skin And Wound $786 9 payments
  6. Integra Recon-Skin And Wound $786 9 payments
  7. LAPIPLASTY SYSTEM $712 8 payments
  8. VITOSS $349 4 payments
  9. Stimulan $312 3 payments
  10. 5MS $266 2 payments
  11. Other $5,744 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

262

Median for Podiatry: 160

Drug cost

$2,543

Median for Podiatry: $2,368

Branded share of claims

12.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 95 $630
Ketoconazole Generic 24 $581
Ciclopirox Generic 13 $357
Cephalexin Generic 40 $278
Gabapentin Generic 46 $263
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 19 $199
Allopurinol Generic 12 $173
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$410,291

Of which drugs: $180,637

Medicare patients

664

Average age 80

Services billed

4,287

351 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 43%
Ischemic heart disease 41%
Diabetes 36%
Depression 30%
Atrial fibrillation 26%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 68 201 $1,048

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record